Johnson & Johnson, through its Janssen Pharmaceutical Companies, is a major player in neurodegenerative disease research and development. The company has been actively developing therapies for Alzheimer's disease, Parkinson's disease, and other CNS disorders. Janssen's neuroscience portfolio combines small molecule approaches with antibody therapies, often developed through strategic collaborations with biotechnology partners.
| Compound | Mechanism | Phase | Status |
|---|---|---|---|
| JNJ-63733657 | Anti-tau antibody | Phase 2 | Ongoing |
| JNJ-63733657 + ACI-35 | Tau vaccine collaboration | Phase 1b/2a | With AC Immune |
Janssen's tau antibody program targets pathological tau aggregates, which are a hallmark of Alzheimer's disease and other tauopathies. The company's collaboration with AC Immune has yielded multiple therapeutic candidates targeting different tau epitopes.
Janssen previously investigated BACE inhibitors for Alzheimer's disease, but these programs were discontinued following industry-wide setbacks with this mechanism. The company has since pivoted toward alternative approaches including tau immunotherapy and neuroinflammation targets.
Janssen is exploring modulation of neuroinflammatory pathways as a therapeutic approach for AD. This includes targeting microglial activation and complement pathways that contribute to neurodegeneration.
| Compound | Mechanism | Phase | Status |
|---|---|---|---|
| JNJ-40411813 | mGluR2 positive modulator | Discontinued | - |
| Parkinson's gene therapy | AAV-based delivery | Preclinical | Research |
Janssen has explored multiple mechanisms for Parkinson's disease treatment, including glutamate modulation and gene therapy approaches. The company's gene therapy programs leverage expertise from its broader AAV platform capabilities.
Janssen utilizes advanced antibody engineering platforms for developing therapeutic antibodies targeting CNS antigens. Their technologies include:
The company has invested in AAV-based gene therapy platforms applicable to neurodegenerative diseases. This includes capabilities in vector design, manufacturing, and CNS delivery.
Janssen's collaboration with AC Immune, initiated in 2015 and expanded in 2020, focuses on tau-targeting therapeutics:
Janssen maintains research collaborations with leading academic institutions for neurodegenerative disease research, including programs at:
Janssen's Alzheimer's programs have generated clinical data including:
Janssen differentiates itself through: